RUA Life Sciences (FRA:AOHA) Net Interest Margin (Bank Only) %

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:AOHA RUA Life Sciences PLC FRA:AOHA
48 GF Score
Price €0.24
GF Value €0.14
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is RUA Life Sciences Net Interest Margin (Bank Only) %?

Net Interest Margin (Bank Only) % only applies to banks.

FRA:AOHA
48GF Score
RUA Life Sciences PLC FRA:AOHA
Net Interest Margin (Bank Only) % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is RUA Life Sciences (FRA:AOHA) Overvalued in 2026?

Based on GuruFocus' analysis, RUA Life Sciences stock appears to be overvalued. The current stock price of €0.24 is trading 72.9% above its estimated GF Value™ of €0.14. GuruFocus considers RUA Life Sciences to be Significantly Overvalued.

Key valuation signals for FRA:AOHA:

  • Net Interest Margin (Bank Only) %:
  • GF Value™: €0.14 vs. price of €0.24 (72.9% above fair value)
  • GF Score™: 48/100 with 5 warning signs

No single metric tells the full story. See the FRA:AOHA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

RUA Life Sciences Business Description

Other Exchanges RUA:UK
Address 2 Drummond Crescent, Scotland, Irvine, Ayrshire, GBR, KA11 5AN
RUA Life Sciences PLC is engaged in the contract design and manufacture of medical devices, exploiting the value of its IP and know-how, and developing cardiovascular devices. The Biomaterials segment is a licensor of Elast-Eon polymers to the medical device industry. The Medical Devices & Components segment is an end-to-end contract developer and manufacturer of medical devices and an implantable fabric specialist, which generates maximum revenue. The Vascular segment focuses on the development and commercialisation of the Group's Elast-Eon sealed Vascular Graft products. The Structural Heart segment focuses on the development of the Group's tri-leaflet polymeric heart valves. Geographically, it operates in Europe, North America, Middle East, Asia Pacific, and Africa.
48GF Score

Get the complete analysis for FRA:AOHA

Net Interest Margin (Bank Only) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.24
Price
€0.14
GF Value